Head to Head Review: SeaStar Medical (NASDAQ:ICU) vs. CochLear (OTCMKTS:CHEOY)

CochLear (OTCMKTS:CHEOY) and SeaStar Medical (NASDAQ:ICU) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, profitability, risk, earnings and dividends.

Volatility & Risk

CochLear has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, SeaStar Medical has a beta of -1.05, meaning that its stock price is 205% less volatile than the S&P 500.

Insider & Institutional Ownership

1.7% of SeaStar Medical shares are held by institutional investors. 0.7% of SeaStar Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares CochLear and SeaStar Medical”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CochLear	$1.53 billion	3.60	$251.85 million	N/A	N/A
SeaStar Medical	$1.23 million	13.01	-$12.15 million	($4.80)	-0.83

CochLear has higher revenue and earnings than SeaStar Medical.

Profitability

This table compares CochLear and SeaStar Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CochLear	N/A	N/A	N/A
SeaStar Medical	-828.62%	-146.29%	-96.48%

Analyst Ratings

This is a summary of current ratings and price targets for CochLear and SeaStar Medical, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CochLear	0	4	0	1	2.40
SeaStar Medical	1	0	1	0	2.00

CochLear currently has a consensus target price of $117.00, suggesting a potential upside of 178.90%. SeaStar Medical has a consensus target price of $8.00, suggesting a potential upside of 100.00%. Given CochLear’s stronger consensus rating and higher possible upside, equities analysts plainly believe CochLear is more favorable than SeaStar Medical.

Summary

CochLear beats SeaStar Medical on 9 of the 13 factors compared between the two stocks.

About CochLear

Cochlear Limited provides implantable hearing solutions for children and adults worldwide. It offers cochlear implant systems, sound processor upgrades, bone conduction systems, accessories, and other products. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.

About SeaStar Medical

SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is headquartered in Denver, Colorado.